Sienna Biopharma (SNNA) Stock Offering; First Hancock Jaffe's (HJLI) VenoValve Successfully Implanted; Camber Energy (CEI) Evaluating M&A Opportunities; MannKind (MNKD) Upcoming Key Date
Shares of Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) plunged more than 15% in the extended session Tuesday after the company said that it has commenced a proposed underwritten public offering of its common stock, adding that the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Sienna Biopharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics.
**
Hancock Jaffe Laboratories Inc. (Nasdaq:HJLI) shares surged $0.01 (or +0.63%) to $1.60 on Tuesday's trading session after the company reported the successful start of its VenoValve first-in-human study in Bogota, Colombia
According to HJLI, the first VenoValve was implanted in a patient and the procedure went very well. The patient was walking the day after the surgery, the VenoValve appears to be functioning as it should, and the patient shows no early signs of thrombosis, reflux, or other adverse events.
HJLI has enrolled additional patients for the VenoValve study and the company will provide a further update following the next implantations - which are currently scheduled to take place in March -, expecting to release preliminary data on the first group of VenoValve recipients at the end of the second quarter this year.
HJLI's VenoValve was developed to treat severe cases of chronic venous insufficiency (CVI), a debilitating condition often associated with open venous ulcers and intense pain. Approximately 2.6 million patients in the U.S. suffer from CVI due to reflux in the deep venous system, and there are currently no FDA approved treatments for the condition.
HJLI specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases.
**
Shares of Camber Energy, Inc. (NYSEAmerican:CEI) climbed $0.10 (or +19.48%) to $0.63 on Tueday as the company reported that it has received a letter of notification from the NYSE Regulation that it is back in compliance with three of the NYSE American continued listing standards - adding that it is currently below compliance with the NYSE American continued listing requirement relating to low priced securities -.
Camber also said that it is now better positioned for acquisition and merger opportunities of which the company is actively evaluating.
Camber Energy is a growth-oriented, independent oil and gas company engaged in the development of crude oil, natural gas and natural gas liquids in the Texas Panhandle as well as other basins.
**
MannKind Corp. (Nasdaq:MNKD) will release its fourth quarter and full year 2018 financial results before the opening bell on Tuesday, February 26.
MannKind focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.
****
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer